Skip to main content
OpenTrials
Completed

NCT Number: NCT03154736

Scaling-up Packages of Interventions for Cardiovascular Disease Prevention in Selected Sites in Europe and Sub-Saharan Africa: An Implementation Research

Cardiovascular disease is the leading cause of death in the world. 17.5 million people died in 2012 due to a cerebrovascular disease (31% of all causes of death). In Europe more than 50% of deaths are due to cardiovascular disease. The mortality rate for cardiovascular disease is higher in the lower socio-economic levels. Three-quarters of deaths from cardiovascular disease occur in developing countries. According to estimates in 2030, cardiovascular disease will be responsible for more deaths than the sum of infectious, nutritional, maternal and perinatal diseases in developing countries.

Measures to prevent cardiovascular risk factors have been shown to be effective.

The lack of an adequate primary care network in developing countries limits the screening and treatment of patients with cardiovascular risk factors. As a result, these patients do not benefit from adequate prevention, are diagnosed late and remain disabled or die at a young age, resulting in significant additional costs for families but also at the macroeconomic level.

Interventions are possible on a large scale (policies against tobacco and adverse dietary behavior, promote physical activity, etc.). Actions are possible on an individual level, both in primary prevention (control of cardiovascular risk factors) and secondary prevention, where many treatments have proved their effectiveness. These interventions are effective and cost-effective from a macroeconomic perspective. It was estimated that the cost of such interventions would not exceed 4% of health expenditure in developing countries and 1-2% in rich countries.

The World Health Organization insists on the importance of the triad composed by the patient and his family, community and health professionals. Results are possible only when these three components work together for the same purpose. Numerous studies show the benefit of the involvement of patients in their care in the rich countries and in the developing countries.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Disease Cardiovascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Carhaix Plouguer, Carhaix-Plouguer, France

Loading trial locations.

About this study

This project builds on advances in the treatment of HIV / AIDS in Sub-Saharan Africa and in chronic disease management through the WHO Innovative Care for Chronic Conditions Framework.

These projects emerged from the observation that the rich country model of care (patient-centered, hospital-centered and specialist approach with regular clinical and paraclinic follow-up) was not transferable to developing countries, The limitation of human, technical and financial resources.

A paradigm shift is needed to improve cardiovascular disease control in a more cost-effective manner.

The SPICES project plans to integrate the current knowledge of new studies to improve the prevention and control of cardiovascular disease in high-, middle-, and low-income countries.

Rich countries and developing countries will therefore be involved in the study: the selected sites are France, the United Kingdom, Belgium, South Africa and Uganda.

This study is a stage of observation in the different countries which will make it possible to make an inventory of the places and to target the most adapted interventions.

The main objective is to define the representations on cardiovascular prevention and the follow up of patients with cardiovascular disease or FDRCV.

The secondary objectives are to identify:

  • the brakes in the management of patients with CVD or FDRCV
  • the institutional care network for these patients
  • Identify the "informal" care network, that is, family and community caregivers and within them the potential barriers and facilitators to their care.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Persons aged over 18 years.
  • Persons able to express their consent
  • Patients with FDRCV or CVD who gave written consent to participate in the study.
  • Family caregiver of patients with FDRCV or CVD with written consent to participate in the study

Exclusion criteria

  • Refusal to participate in the study
  • Patients and / or family caregiver who can not express their consent (illiterate, severe cognitive or psychiatric disorders)
  • Patients under judicial protection (guardianship and curatorship)
  • Pregnant women
  • Patients under 18 years of age

Treatment and study plan

interview

Other

Individual interview and group interview Socio-economic questionnaire

Primary outcomes

  1. Experiences of patients with cardiovascular disease

    Time frame: 1 day

    The representations on cardiovascular prevention and the follow-up experience of patients with cardiovascular disease or CVRF will be defined by questionnaire

Secondary outcomes

  1. The obstacles of patients with cardiovascular disease

    Time frame: 1 day

    The obstacles to the management of patients with CVD or CVRF will be identified by questionnaire

  2. Institutional care network

    Time frame: 1 day

    The institutional care network for these patients will be identified by questionnaire

  3. Informal or informal care network

    Time frame: 1 day

    The "informal" care network, that is to say, family or community caregivers and within them the brakes and facilitators will be identified by questionnaire

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Collaborators

  • ERCR SPURBO

Registry information

Acronym: SPICES_PHASE_1

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
May 16, 2017
Registry last updated
Apr 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.